EUCTR2018-001680-24-AT进行中（未招募）1 期
Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation - ALiKE
Medical University of Vienna - Abteilung für Thoraxchirurgie0 个研究点目标入组 110 人开始时间: 2018年6月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All bilateral lung transplantation
- •Age > 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •Pediatric patients (age < 18 years)
- •Pre-transplant colonization of Burkholderia or resistant Mycobacterium abscessus
- •Wound infection at the time of randomization
- •Inclusion in other studies
研究者
相似试验
招募中
不适用
Comparing the use of Everolimus and Tacrolimus reduced dose versus Mycophenolate Sodium and Tacrolimus reduced dose in Liver Transplant patientsiver transplantation immunossupression, hepatic graft rejection and loss, receptor death, immunosuppressive drug myelotoxicity, posttransplant diabetes mellitus, posttransplant dyslipidemia, cytomegalovirus events, hepatic artery thrombosis, bile duct complications, operative wound complications, incisional hernia, postoperative kidney failure, proteinuria, discontinuation of the immunosuppressive regimen.Liver transplantationeverolimustacrolimusmycophenolate sodium.E04.210.650D02.540.505.810D02.540.505.760.500D02.241.081.193.678RBR-9k66x6Hospital Geral de Fortaleza
进行中（未招募）
1 期
Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinomaEverolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%EUCTR2013-002524-16-SEDept of Oncology. Haukeland University Hospital40
进行中（未招募）
1 期
Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinomaEverolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 100000004864EUCTR2013-002524-16-DKDept of Oncology. Haukeland University Hospital38
招募中
不适用
Management of the combination of tacrolimus with azoles: effect of tacrolimus formulation on drug-drug interaction magnitudeMycoses due to opportunistic pathogensfungal infection in patients with immune deficiencies who would otherwise not be infected10017528NL-OMON54925niversitair Medisch Centrum Groningen24
已完成
4 期
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal TransplantTransplantation InfectionCytomegalovirus InfectionsNCT02084446Ronaldo de Matos Esmeraldo, MD120